Osteopontin b and c Splice isoforms in Leukemias and Solid Tumors: Angiogenesis Alongside Chemoresistance

Akram Mirzaei¹, Saeed Mohammadi¹,²*, Seyed H Ghaffari¹*, Marjan Yaghmaie¹, Mohammad Vaezi¹,², Kamran Alimoghaddam¹,², Ardeshir Ghavamzadeh¹,²

Abstract

Osteopontin (OPN) is a glycoprotein involved in regulation of various influences on tumor progression, such as cellular proliferation, apoptosis, angiogenesis, and metastasis. Vascular endothelial growth factor (VEGF) is a secreted molecule supporting angiogenesis in various cancers through activation of the P13K/AKT/ERK1/2 pathway. OPN and VEGF have a number of isoforms with various activities. In spite of the well-defined association between OPN and VEGF isoform expression and cure rate for solid tumors, there is a scarcity of information as to any association in leukemia. Based on the critical role of OPN in cell survival, it seems reasonable to hypothesize that OPN and VEGF isoform expression levels may impact on chemoresistance and relapse in leukemia the same as in solid tumors. Hence, the aim of our review was to explain relationships between OPN and VEGF isoforms and angiogenesis and related pathways in chemoresistance of leukemia and solid tumors. Our findings demonstrated that OPNb and OPNc alongside with VEGF isoforms and other gene pathways are involved in angiogenesis and also might promote chemoresistance and even recurrence in leukemia and solid tumors. To sum up, targeting OPN isoforms, particularly b and c, might be a novel therapeutic strategy for the treatment of leukemia as well as solid tumors.

Keywords: Osteopontin- splice isoforms- leukemia- solid tumors- angiogenesis

Introduction

Osteopontin Structure

Osteopontin (OPN) is a glycoprotein with 314 amino acids which is investigated in osteoblasts for the first time. OPN is also recognized as BPP, BSPI, TAP, ETA-I, TSP1, USP and SPP1 terms. It is expressed in multiple tissue types and secreted form could be involved in cell attachment and signal (Zahedpanah et al., 2016b; Mohammadi et al., 2017a).

The Human OPN gene is encoded by a single-copy gene on chromosome 4q21-q25 with seven exons (Young et al., 1990) (Figure1). It contains numerous highly conserved extracellular structural domains, including: aspartate domain, RGD sequence, SVVYGLR sequence, thrombin cleavage site, calcium-bonding domain and heparin interconnecting domain (Anborgh et al., 2010; Cao et al., 2012). Likewise, protease cleavage sites are probably pivotal in adjusting its activity (Figure 2).

It is well proved that OPN assists as a substrate for thrombin and matrix metalloproteinases like MMP2, MMP3, MMP7, MMP9 and MMP12. Therefore, it can bind to the extracellular matrix proteins, fibronectin, and collagen. OPN was recognized with seven protein interactions: ITGAV, IGFBP5, PDLM17, CD44, ITGA5, CTNNBL1, and SGTa (Ramaiah and Rittling, 2007). It binds to cell surface receptors through integrins such as vitronectin receptor (Mazzali et al., 2002) αVβ3, α4β1, α9β1, CD44 (Smith et al., 1999; Zahedpanah et al., 2016b) as well as to extracellular matrix components such as collagen and matrix metalloproteinase. Integrin receptors identified with both the RGD and the SVVYGLR motifs (Ramaiah and Rittling, 2007).

Osteopontin in Cancer

OPN is involved in proliferation, migration, and cellular invasion, as well as preventing cell apoptosis and autophagy with binding integrin αVβ3. It has been joined with some markers in various types of cancer that are known as functionally converging biomolecules (Weber, 2011). The excessive expression of OPN in invasive cancer cells indicates a key role of OPN in cancer progression (Thalmann et al., 1999; Furger et al., 2001). The relationship of OPN with various cancers and stages of disease progression is an important goal in interfering of OPN in the treatment process. Diverse levels of OPN are reported in some cancers containing, leukemia (Zhang et al., 2010a; Liersch et al., 2012; Mohammadi et al., 2017a; Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, 2Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran, Iran. *For Correspondence: saeedm_58@yahoo.com, shghaffari200@yahoo.com

Asian Pacific Journal of Cancer Prevention, Vol 19 615
In the contrary, overexpression of OPNc decreased activity in scratch closure and proliferation. On expression. Meaningfully overexpression of OPNa and OPNb were expressed meaningfully in tumor and non-tumor ovarian samples, while specifically OPNc was expressed in ovarian tumor samples.

Tilli et al., (2011) presented that OPNc isoform via activation of PI3K/Akt signaling pathway plays a key role in tumorigenesis, metastasis, and invasion in the OvCar-3 cell (ovarian cancer) and IOSE cells (ovary epithelial). Tang et al., (2013) demonstrated that gastric cancer cell survival strongly promoted by OPNb isoform. Furthermore, OPNc efficiently stimulated gastric cancer cell survival strongly promoted by OPNb isoform.

Molecular Mechanisms of OPN in Cancers

Various OPN function in cancer is performed via direct connection of OPN with integrin or/and CD44 which lead to activation of different pathways in malignant cells (Liaw et al., 1995; Irby et al., 2004; Bellahcene et al., 2008). OPN molecule is able to activate several signaling transduction pathways via a complex signaling network in various cancer models such as prostate cancer, gastrointestinal cancers, melanoma, myeloma, breast cancer and lung cancer (Bellahcene et al., 2008). For instance, a recent report showed that tumor-promoting functions of OPN are related to NF-kB/PI3-K/Akt pathway activation with subsequent up-regulation of BCL-XL in solid tumors (Lee et al., 2007; Sun et al., 2008; Zhao et al., 2008).

Our previous study in leukemia cells showed that OPN plays a role in activation the signal pathway of the PI3K/Akt, following the binding to avb3 integrin or CD44. Furthermore, OPN causes mTOR phosphorylation in Ser-2448 (Zahedpanah et al., 2016a; Mohammadi et al., 2017d) (Figure 4). Previously in some studies, we reported that in parallel with OPN knockdown by using siRNA, AKT/mTOR/PTEN/β-catenin expression levels were significantly decreased in AML cell lines and also enhanced apoptosis in AML blasts and CD34+/CD38- CD123+ leukemic stem (Mohammadi et al., 2016a;
Table 1. Summary of OPN Functions and Clinical Significance in Human Cancers.

| Cancer type                  | Biological functions                                                                 | Clinical significance                                                                 | Refs.                |
|------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------|
| Prostate                     | - hOPN mRNA was over-expressed in both human prostate cancer cell lines and in clinical human specimens. - Expression of OPN and IL-8, are related to metastasis and angiogenesis in prostate cancer. | - OPN is paracrine and autocrine mediator of growth and progression in prostate cancer. - In prostatectomy specimens, expression of OPN is related to disease recurrence. | (Thalhammer et al., 1999; Caruso et al., 2008) |
| Leukemia                     | - PI3K/AKT signaling by Tax protein of HTLV-1 might induce leukemogenesis. - Serum OPN increased in chronic and acute hematologic malignancy. - Curcumin as a NF-κB inhibitor can be prompted apoptosis and inhibited proliferation of AML cell lines and primary isolated AML cells. - Parthenolide decreases protein level of OPN and mRNA expression of Akt1, mTOR, PTEN, and β-catenin in AML cells. | - The level of OPN expression is known as an independent prognostic marker in AML. - Parthenolide has several applications including apoptosis and reduced expression of OPN gene in AML cells. - OPN knockdown by OPN siRNA decreased colony numbers in the Leukemic stem cells. | (Furger et al., 2001; Zhang et al., 2010a; Liersch et al., 2012; Zahed panah et al., 2016; Mohammadi et al., 2016b;Mohammadi et al., 2017c) |
| Pancreatic                   | - OPN is a candidate tumor marker for pancreatic cancer. - Overexpression of OPN may be related to aggressive phenotype. | - OPN might be a diagnostic marker in patient's serum with pancreatic cancer. - Knockdown of OPN can be used as an effective therapeutic strategy. | (Koopmann et al., 2004; Kolb et al., 2005;Collins et al., 2012) |
| Renal cell carcinoma         | - OPN via P65/NF-kB signaling pathway may be involved in the clear cell renal cell carcinoma progression. | - High OPN plasma levels are related to poor prognosis and metastases in renal cell carcinoma patients. | (Ramankulov et al., 2007; Mutusan-lijâş et al., 2011) |
| Breast                       | - Overexpression of OPN has been related to tumor progression in breast cancer. | - Overexpression of OPN isoforms (OPNC) was related to poor prognosis, tumor grade, and stage of triple negative breast tumors. | (Patani et al., 2008; Wang et al., 2008; Macri et al., 2009; Saleh et al., 2016) |
| Gastrointestinal stromal tumors | - OPN has anti-apoptotic effects towards imatinib in gastrointestinal stromal tumors. These effects are mediated by Mcl-1-up-regulation through β-catenin pathway. - Mitosis in gastrointestinal stromal tumor is related to OPN/CD44 interaction. | - Expression of OPN was related to poor prognosis in gastrointestinal stromal tumor malignancies. | (Hsu et al., 2010b; Hsu et al., 2014) |
| Non-small-cell lung          | - Expression of OPN in non-small-cell lung cancer was strongly related to tumor proliferation. - OPNα binding to recombiant integrin αvβ3 efficiently inhibited by AOM1. | - Overexpression of OPN in tumor samples was related to metastasis of non-small-cell lung. - A level of OPN in early-stage of non-small-cell lung cancer was associated with therapeutic response and survival. - Carboplatin in combination with anti-OPN monoclonal antibody was used for the inhibition of the tumor growth in mice model. | (Zhang et al., 2010b; Blasberg et al., 2010; Shojaei et al., 2012) |
| Lung                         | - OPN has an important role in cell proliferation and lung cancer invasiveness. - Expression of beclin-1 gene led to autophagy induction, cancer cell growth inhibition and angiogenesis inhibition. | - OPN is known as a marker for invasive lung cancer. - Expression of both OPN and beclin-1 genes are known targets for prevailing on radioresistance via autophagy controlling. | (Zhao et al., 2011 Chang et al., 2012) |
| Colorectal                   | - Over-expression of OPN in colorectal cancer leads to cell progression and inhibiting cell autophagy via activating the p38 MAPK signaling pathway. | - OPN might be a therapeutic biomarker in patients with colorectal. | (Huang et al., 2017) |
| Ampullary                    | - Overexpression of OPN was associated with tumor-related macrophages. | - Overexpression of osteopontin in bulky Ampullary cancer predicts recurrence of the disease in patients. | (Hsu et al., 2010a) |

Movahedi et al., 2016b; Mohammadi et al., 2017b; Panah et al., 2017).

Soutto and Servetas studies revealed that TFF1 (tumor suppressor) could inhibit β-catenin and NF-κB via negative regulation of Akt/GSK-3β (Soutto et al., 2014; Soutto et al., 2015a; Soutto et al., 2015b; Servetas et al., 2016). OPN protein can trigger MEK/ERK1/2 pathway in cancer in order to stimulate growth and metastasis in the tumor (Sun et al., 2008).

The MMP family has an essential role in tumor invasion and metastasis. OPN promoted metastasis through MMP-2, MMP-7, MMP-9 and VEGF, and uPA (Sun et al., 2008; Georges et al., 2010; Likui et al., 2011). There is a positive relationship between OPN, VEGF, and COX-2, and they are able to induce angiogenesis and metastasis in cancer. COX-2 inhibitors have antitumor activity via OPN down-regulation, with occlusion of OPN regulatory network (Tang et al., 2008; Zagani et al., 2009) (Table 3).

**OPN and VEGF**

VEGF and OPN are two markers that have recently been identified as a biomarker for prognosis in various cancers (Cui et al., 2009; Mirzaei et al., 2017b). OPN and VEGF are involved in proliferation, invasion, tumor progression and finally in angiogenesis of cancer cells (Kumar et al., 2013). There is a synergistic effect between VEGF and OPN. For example, OPN can stimulate VEGF (Chakraborty et al., 2008; Dai et al., 2009; Tili et al., 2012; Kumar et al., 2013; Wahl et al., 2013; Raja et al., 2014) by the integrin αvβ3 in umbilical artery cells (Infanger et al., 2008).
Chakraborty et al., (2008) confirmed that OPN stimulates tumor progression and angiogenesis by activation of some pathways such neuropilin-1/Brk/NF-κB/ATF-4 signaling in various grades of cancer. Moreover, they indicated that OPN via using some mechanisms stimulates VEGF-dependent cancer progression and angiogenesis.

VEGF can stimulate integrin αvβ3, OPN, and thrombin which leads to accelerated migration activity through endothelial cells at some point of angiogenesis (Senger et al., 1996). In endothelial cells, OPN stimulates angiogenesis and induces VEGF via three main pathways including, phosphorylation and activation of PI3K/AKT and ERK1/2 cascades and mutually, VEGF induces OPN with integrin αvβ3 and thrombin (Dai et al., 2009; Ramchandani and Weber, 2015).

Our previous studies in leukemia stated that Sorafenib and Thalidomide as VEGF inhibitors in combination with arsenic trioxide and curcumin have synergistic impacts on inhibition of cell proliferation and promotion of apoptosis in AML cells without FLT3 mutation (Haghi et al., 2017; Salemi et al., 2017) (Table.4).

**Discussion**

OPN splicing isoforms have been observed and measured in various cancers, including esophagus, stomach, liver, pancreas, brain, breast, head, neck, soft tissue sarcoma and AML (Lazar et al., 2010; Mirzaei et al., 2017a; Mirzaei et al., 2017b). With this regard, it has not yet been determined a clear and precise relationship between different splicing isoforms of OPN with VEGF in various cancers. As shown in previous studies, OPN splicing isoforms have different interactions with VEGF and angiogenesis in various cancers. Li et al., (2014) concluded that among all OPN splicing isoforms, OPNc...
and OPNb, play tumorigenic roles in prostate cancer cells and also these two isoforms impel secretion higher levels of VEGF, MMP2, and MMP9 in prostate cancer cells (Tilli et al., 2012) while OPNa did not affect prostate cancer cells.

Evidence of our previous study for the first time declared that the two main OPN isoforms including OPNb and OPNc have an important role in angiogenesis and chemoresistance in AML through STAT3/VEGFC/β-catenin genes pathways. With inhibition of OPN splicing isoforms with simvastatin and special siRNA, we demonstrated a decrease in STAT3, VEGFC, and β-catenin genes that they probably are located in downstream of OPNb and OPNc isoforms (Mirzaei et al., 2017a; Mirzaei et al., 2017b). OPNa still has no role in angiogenesis in AML cell lines according to our reports and also study conducted by Li et al., (2014).

Some studies explained that OPNc decreases VEGF expression and so reduces tubule formation in non-small cell lung cancer while OPNb acts through its effect on αvβ3 receptor integrin. OPNa with αVβ3 receptor binding integrin caused VEGF secretion and increased angiogenesis (Donati et al., 2005; Goparaju et al., 2010; Zhang et al., 2010b; Shojaei et al., 2012).

Figure 3. Different OPN Variants and Gen-Bank Accession Numbers. OPNa has six translated exons, while OPNb has a deletion of exon 5, and OPNc has a deletion of exon 4.

Figure 4. Molecular Mechanisms of Osteopontin. OPN in connecting with CD44 or/and integrin αVβ3 cause growth and metastasis via activation of some pathways such as cell survival, cell proliferation, angiogenesis and migration.
Table 3. Summary of Molecular Mechanisms of OPN Functions and Clinical Significance in Human Cancers

| Cancer type | Biological functions | Clinical significance | Refs. |
|-------------|----------------------|-----------------------|-------|
| Colon       | - Overexpression of OPN via interaction with CD44 was associated with tumor stage, reduced intercellular adhesion, proliferation and increased CD31 positive microvessel counts in the colon cancer. | - OPN has critical role in human colon cancer progression. | (Izzy et al., 2004) |
| Gastric     | - OPN, COX-2, and VEGF Levels are associated with lymph node metastasis, stage of cancer and microvessel density in gastric cancer. | - The interaction between OPN and CD44/VEGF promotes ECM-derived survival that affects progression of gastric cancer. | (Lee et al., 2007; Tang et al., 2008; Souto et al., 2015a; Souto et al., 2015b; Servetas et al., 2016) |
|             | - β-catenin and α4, β1, and β3 integrin genes, Locked NF-κB activity, inhibits expressions of XIAP and Bel-2 and Bel-XL over-expression. | - Metastasis and angiogenesis in gastric cancer promoted by COX-2, OPN, and VEGF. | - Lack of TFF1 can be a significant step in promoting the oncogenic activation of β-catenin and gastric tumorigenesis mediated by H. pylori. |
| Hepatocellular | - OPN can induce metastasis and tumorigenesis via inhibition apoptosis in hepatocellular carcinoma cell. | - Silencing of OPN by siRNA can prevent hepatocellular carcinoma cell growth and sensitized these cells to chemotherapeutic agents. | (Sun et al., 2008; Zhao et al., 2008) |
| Colorectal  | - Cyclooxygenase-2 inhibitor with antitumor activity was down-regulated OPN via blockade of NR4A2 and Wnt signaling pathway. | - Parecoxib quickly down-regulate OPN in Intestinal polyps. | (Zagani et al., 2009; Georges et al., 2010; Likut et al., 2011) |
|             | - Expression of OPN protein in colorectal cancer tissues was more than in non-tumor tissues. | - Rosfexib was reduced the orphan nuclear receptor NR4A2 levels in adenomas from patients. | - Targeting OPN with RNAi can increase radio-sensitivity and suppress invasion of colorectal cancer cells |
| Leukemia    | - Upregulation of OPN, significantly up-regulate AKT/mTOR/PTEN/β-catenin/NF-kB1 expression levels in the enriched CD34+/AML cells. | - Daunorubicin in combination with curcumin has more growth inhibition effect on CD34+/CD38-AML. | (Mohammadi et al., 2016b; Mohammadi et al., 2017a; Mohammadi et al., 2017b; Panah et al., 2017) |
|             | - Osteoblasts promote enrichment of leukemia stem cell in response to daunorubicin and curcumin via OPN/STAT-3/VCAM-1/IL-6/CXCL-12 up-regulation in AML cell lines. | - OPN seems to be main molecular marker in AML blast and leukemic niche for targeted treatment. | - Knockdown of OPN with siRNA increased the cytotoxic effects of parthenolide on AML cell lines and decrease AKT, mTOR, β-catenin, and PTEN expression. |

Table 4. Summary of OPN and VEGF Functions and Clinical Significance in Human Cancers

| Cancer type | Biological functions | Clinical significance | Refs. |
|-------------|----------------------|-----------------------|-------|
| Breast      | - Expressions of VEGF and OPN were associated with breast tumor kinase, neuropilin-1, NF-kB, and activating transcription factor-4 signaling cascades in various stages of breast cancer. | - Expression of VEGF by tumor cells and neovascularization by VEGF are two important essential roles of tumor progression of OPN. | (Chakraborty et al., 2008; Raja et al., 2014) |
|             | - OPN induces NF-kB p65 activation that leads to expression of VEGF and HIF1α in response to hypoxia. | - OPN via expression of VEGF/HIF1α dependent pathway and also activation of NF-kB/ILK in response to hypoxia can control angiogenesis and eventually breast cancer progression. | |
|             | - Overexpression of HIF1α and OPN exert in pre-neoplastic and early stage of breast cancer. | - Daunorubicin in combination with curcumin has more growth inhibition effect on CD34+/CD38- AML cells. | |
| Lung        | - Knockdown of OPN can reduce the formation of malignant pleural effusion. | - OPN was involved in formation of malignant pleural effusion of lung cancer likely by promoting VEGF secretion. | (Cui et al., 2009) |
| Endothelial | - OPN enhances the expression of VEGF via the AKT and ERK phosphorylation. | - Anti-OPN antibody has more anti-angiogenesis effect in comparison to anti-VEGF antibody in vivo. | (Dai et al., 2009) |
|             | - VEGF induced by OPN activates PI3K/AKT and the ERK1/2 pathway. | | |
| Prostate    | - Overexpression of OPNC and OPNb in line with MMP-2, MMP-9, and VEGF gene expression could be enhanced invasion, migration, proliferation and tumor growth via PI3K signaling. | - Down-regulating of OPNC and OPNb expression could prevent progression of prostate cancer. | (Tilli et al., 2012) |
| Retinal Glial | - The neuro-protective effects of OPN with autocrine effects interceded by the release of VEGF from Müller cells. | - Pharmacological blockers of VEGFR2, neutralizing anti-VEGF antibody can abrogate OPN effect. | (Wahl et al., 2013) |
| Melanoma    | - Expression and activation of VEGF, ABCG2, and ERK1/2 were induced by OPN. | - Inhibition of OPN might be a novel therapeutic strategy for treatment of malignant melanoma. | (Kumar et al., 2013) |
Lazar et al., (2010) found that OPNc is expressed mainly in pancreatic cancer tissues and promoted by nicotine and plays its role by up-regulating the expression of MMP-9 and VEGF. Therefore, high levels of OPNc, VEGF, and MMP-9 are related to an aggressive phenotype. OPNa, VEGF, and thrombin through its effect on αvβ3 receptor integrin, and increases the secretions of VEGF by tumor cells cause progression in lung cancer (Senger et al., 1996; Blasberg et al., 2010a; Ramchandani and Weber, 2015).

It’s believed that STAT3 is activated in a wide range of cancer cells (Niu et al., 2002) and can regulate metastasis in human cancer cells by promoting tumor angiogenesis (Wang et al., 2011) through the modulation of VEGF expression (Ramchandani and Weber, 2015). Wang et al., (2013) indicated that activation levels of STAT3 and IL-6 were correlated with tumor progression in neoplastic human gastric cancer cells. Many studies have shown that CXCR4/CXCL12/STAT3/VEGF molecular loop over-expression is able to promote tumor cells progression, metastasis and angiogenesis via the stimulation of PI3K/Akt pathway (Liang et al., 2007; Lin et al., 2009; Wang et al., 2011). In agreement with this finding, we have also proved that VEGF/STAT3/ CXCR4 overexpression in mRNA levels in AML cell lines along with OPNb and OPNc is associated with angiogenesis. We demonstrated that simvastatin as a natural OPN inhibitor, hindered AML cell proliferation and along with inhibition of the three OPN isoforms gene expression, decrease in STAT3, VEGFC, and β-catenin gene expression. Hence, there is relevance among OPN isoforms and angiogenesis-associated genes (Mirzaei et al., 2017b; Mohammadi et al., 2017a).

In conclusion, taken together, OPNb and OPNc alongside VEGF isoforms and other genes pathways involved in angiogenesis might be promoted chemoresistance and even recurrence in leukemia and solid tumors. Likewise, OPNb and OPNc have potential to consider as molecular candidates for detection of minimal residual disease and determination of remission in AML patients. Our findings declared that targeting OPN isoforms particularly b and c in combination with anti-VEGF agents might be a novel therapeutic strategy for the treatment of leukemia as well as solid tumors.

Abbreviations
- OPN: Osteopontin; VEGF: Vascular endothelial growth factor; ERK1/2: extracellular signal-regulated kinase 1/2 pathway; PI3-K: Phosphoinositide 3-kinase; BPP: bone phosphoprotein; BSPI: bone sialoprotein 1; TAP: transformation-associated phosphoprotein; TSP1: tumor-secreted phosphoprotein 1; ETA-1: early T-lymphocyte activation; USP: Urinary stone phosphoprotein; SPP1: Matrix metalloproteinase; ITGAV: Integrin alpha-V; IGFBP5: Insulin-like growth factor-binding protein 5; ITGAV: integrin alpha 5; SGTA: Small glutamine-rich tetraicopeptide repeat; Mel-1: Myeloid cell leukemia 1; ER: endoplasmic reticulum; NF-κB: nuclear factor-inducing kinase/nuclear factor-κB; MAPK: Mitogen-activated protein kinase; uPA: Urokinase-type plasminogen activator; mTOR: mechanistic target of rapamycin; TFF1: trefoil factor 1; MEK/ERK1/2: Mitogen-activated protein kinase pathway; siRNA: small interfering RNA; COX-2: Cyclooxygenase-2; ECM: Extracellular Matrix; NR4A2: Nuclear receptor subfamily 4, group A, member 2; STAT3: The signal transducers and activators of transcription 3; CXC4: CXC chemokine receptor 4; Brk: breast tumor kinase; ATF-4: activating transcription factor-4

Conflict of interest
The authors declare no conflict of interest.

Acknowledgments
Special thanks to Hematology, Oncology, and Stem Cell Transplantation Research Center at Tehran University of Medical Sciences.

References
Anborgh PH, Mutrie JC, Tuck AB, et al (2010). Role of the metastasis-promoting protein osteopontin in the tumor microenvironment. J Cell Mol Med, 14, 2037-44.
Bellahcene A, Castronovo V, Ogubreke KU, et al (2008). Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nature reviews. Cancer, 8, 212.
Blasberg JD, Goparaju CM, Pass HI, et al (2010a). Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg, 139, 1587-93.
Blasberg JD, Pass HI, Goparaju CM, et al (2010b). Reduction of elevated plasma osteopontin levels with resection of non–small-cell lung cancer. J Clin Oncol, 28, 936-41.
Cao D-X, Li Z-J, Jiang X-O, et al (2012). Osteopontin as biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol, 18, 3923.
Caruso DJ, Carmack AJ, Lokeshwar VB, et al (2008). Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res, 14, 4111-8.
Chakraborty G, Jain S, Kundu GC (2008). Osteopontin promotes vascular endothelial growth factor–dependent breast tumour growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res, 68, 152-61.
Chang S-H, Minai-Tehrani A, Shin J-Y, et al (2012). Beclin1-induced autophagy abrogates radioresistance of lung cancer cells by suppressing osteopontin. J Radiat Res, 53, 422-32.
Collins AL, Rock J, Malhotra L, et al (2012). Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol, 19, 2673-8.
Cui R, Takahashi F, Ohashi R, et al (2009). Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer, 63, 368-74.
Dai J, Peng L, Fan K, et al (2009). Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene, 28, 3412.
Dalal S, Zha Q, Daniels CR, et al (2014). Osteopontin stimulates apoptosis in adult cardiac myocytes via the involvement of CD44 receptors, mitochondrial death pathway, and endoplasmic reticulum stress. Am J Physiol Heart Circ Physiol, 306, 1182-91.
Donati V, Boldrini L, Dell’Omodarme M, et al (2005). Osteopontin expression and prognostic significance in non–small cell lung cancer. Clin Cancer Res, 11, 6459-65.

Furger KA, Menon RK, Tuck AB, et al (2001). The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med, 1, 621-32.

Georges R, Adwan H, Zhivkova M, et al (2010). Regulation of osteopontin and related proteins in rat CC531 colorectal cancer cells. Int J Oncol, 37, 249-56.

Goparaju CM, Pass HI, Blasberg JD, et al (2010). Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol, 5, 1516-23.

Haghi A, Mohammadi S, Heshmati M, et al (2017). Anti-vascular endothelial growth factor effects of soralenb and arsenic trioxide in acute myeloid leukemia cell lines. Asian Pac J Cancer Prev, 18, 1655.

Hsu H-P, Shan Y-S, Lai M-D, et al (2010a). Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival. Cancer Biol Ther, 10, 144-54.

Hsu K-H, Tsai H-W, Lin P-W, et al (2014). Anti-apoptotic effects of osteopontin through the up-regulation of McI-1 in gastrointestinal stromal tumors. World J Surg Oncol, 12, 189.

Hsu K-H, Tsai H-W, Lin P-W, et al (2010b). Clinical implication and mitotic effect of CD44 cleavage in relation to osteopontin/CD44 interaction and dysregulated cell cycle protein in gastrointestinal stromal tumor. Ann Surg Oncol, 17, 2190-2192.

Hsu K-H, Tsai H-W, Lin P-W, et al (2010c). Osteopontin expression is an independent adverse prognostic factor in resectable gastrointestinal stromal tumor and its interaction with CD44 promotes tumor proliferation. Ann Surg Oncol, 17, 3043-52.

Huang R-h, Quan Y-j, Chen J-h, et al (2017). Osteopontin increases in neoplastic and inflammatory conditions. J Gastrointest Surg, 21, 1520-21.

Infanger M, Große J, Westphal K, et al (2008). Vascular endothelial growth factor induces extracellular matrix proteins and osteopontin in the umbilical artery. Ann Vasc Surg, 22, 273-84.

Irby R, McCarthy S, Yeatman T (2004). Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis, 21, 515-23.

Kolb A, Kleeff J, Guweidhi A, et al (2005). Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther, 4, 740-6.

Koopmann J, Fedarko NS, Jain A, et al (2004). Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Prev Biomarkers, 13, 487-91.

Kumar S, Sharma P, Kumar D, et al (2013). Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One, 8, e69116.

Lazar M, Sullivan J, Chipitsyna G, et al (2010). Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells. J Gastrointest Surg, 14, 1566-77.

Lee J-L, Wang M-J, Sudhir P-R, et al (2007). Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res, 67, 2089-97.

Li Z-H, Liao W, Zhao Q, et al (2014). Effect of Cbfal on osteoergic differentiation of mesenchymal stem cells under hypoxia condition. Int J Clin Exp Med, 7, 540.

Liang Z, Brooks J, Willard M, et al (2007). CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun, 359, 716-22.

Liaw L, Skinner MP, Raines EW, et al (1995). The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest, 95, 713.

Liersch R, Gerss J, Schliemann C, et al (2012). Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood, 119, 5215-20.

Likui W, Hong W, Shuwen Z, et al (2011). The potential of osteopontin as a therapeutic target for human colorectal cancer. J Gastrointest Surg, 15, 652-9.

Lin F, Zheng S, Shen Z, et al (2009). Expression levels of CXCR4 and VEGF correlate with blood-borne metastatic progression and outcome in patients with osteosarcoma. Chin Ger J Clin Oncol, 8, 292-5.

Macri A, Versaci A, Lupo G, et al (2009). Role of osteopontin in breast cancer patients. Tumori, 95, 48-52.

Matusan-Iliaš K, Damante G, Fabbro D, et al (2011). Osteopontin expression correlates with nuclear factor-xB activation and apoptosis downregulation in clear cell renal cell carcinoma. Pathol Res Pract, 207, 104-10.

Mazzalli M, Kipari T, Ophaschareonsuk V, et al (2002). Osteopontin-a molecule for all seasons. Exp Oncol, 24, 122.

Mohammadi S, Ghaffari SH, Nikbakht M, et al (2017a). OPN b and c isoforms doublet veto anti-angiogenesis effects of curcumin in combination with conventional AML regimen. Asian Pac J Cancer Prev, 18, 2591-9.

Mohammadi S, Mohammadi S, Ghaffari S, et al (2017b). Osteopontin b and c isoforms: Molecular candidates associated with leukemic stem cell chemoresistance in acute myeloid leukemia. Asian Pac J Cancer Prev, 18, 1707.

Mohammadi S, Ghaffari SH, Shaiiegan M, et al (2016a). Curcumin veto the effects of osteopontin (OPN) specific inhibitor on leukemic stem cell colony forming potential via promotion of OPN overexpression. Int J Hematol Oncol Stem Cell Res, 10, 120.

Mohammadi S, Ghaffari SH, Shaiiegan M, et al (2016b). Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells. Life Sci, 152, 190-8.

Mohammadi S, Nikbakht M, Sajjadi SM, et al (2017a). Reciprocal interactions of leukemic cells with bone marrow stromal cells promote enrichment of leukemic stell cell compartments in response to curcumin and daunorubicin. Asian Pac J Cancer Prev, 18, 831.

Mohammadi S, Zahedpanah M, Ghaffari SH, et al (2017b). Osteopontin plays a unique role in resistance of CD34+/CD123+ human leukemia cell lines KG1a to parthenolide. Life Sci, 189, 89-95.

Mohammadi S, Zahedpanah M, Nikbakht M, et al (2017c). Parthenolide reduces gene transcription of prosurvival mediators in U937 cells. Exp Oncol, 39, 30-5.

Mohammadi S, Zahedpanah M, Nikbakht M, et al (2017d). Parthenolide reduces gene transcription of prosurvival mediators in U937 cells. Exp Oncol, 39, 30-5.

Niu G, Wright KL, Huang M, et al (2002). Constitutive expression of nuclear factor-κB protein in gastrointestinal stromal tumor. Clin Cancer Res, 8, 740-6.

Panah MZ, Nikbakht M, Sajjadi SM, et al (2017). Anti-apoptotic effects of osteopontin via the up-regulation of AKT/
mTOR/β-catenin loop in acute myeloid leukemia cells. *Int J Hematol Oncol Stem Cell Res*, 11, 148-57.

Patani N, Jouhra F, Jiang W, et al (2008). Osteopontin expression profiles predict pathologic and clinical outcome in breast cancer. *Anticancer Res*, 28, 4105-10.

Raja R, Kale S, Thorat D, et al (2014). Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis. *Oncogene*, 33, 2053-64.

Ramahk AK, Ritting S (2007). Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. *Toxicol Sci*, 103, 4-13.

Ramankulov A, Lein M, Kristiansen G, et al (2007). Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. *J Cancer Res Clin Oncol*, 133, 643-52.

Ramchandani D, Weber GF (2011). The cancer biomarker osteopontin: Implications for cancer. *Biochim Biophys Acta Rev Cancer*, 1855, 202-22.

Saleh S, Thompson D, McConkey J, et al (2016). Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells. *BMC Cancer*, 16, 359.

Salemi M, Mohammadi S, Ghaemmagdi A, et al (2017). Anti-vascular endothelial growth factor targeting by anti-vascular endothelial growth factor receptor 2 signaling correlates with clinical implications. *PLoS One*, 8, e75788.

Weber GF (2011). The cancer biomarker osteopontin: combination with other markers. *Cancer Genom Proteom*, 8, 263-88.

Young MF, Kerr JM, Termine JD, et al (1990). cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). *Genomics*, 7, 491-502.

Zagari R, Hamzaoui N, Cacheux W, et al (2009). Parthenolide induces apoptosis in committed progenitor AML cell line U937 via reduction in osteopontin. *Rep Biochem Mol Biol*, 4, 82.

Zahedpanah M, Shaiegan M, Ghaffari SH, et al (2016a). Parthenolide induces apoptosis in committed progenitor AML cell line U937 via reduction in osteopontin. *Rep Biochem Mol Biol*, 4, 82-8.

Zhao B, Sun T, Meng F, et al (2011). Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. *Rep Biochem Mol Biol*, 4, 82-8.

Zhang J, Sakoda Y, Matsushita Y, et al (2009). Osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. *Prostate J*, 127, 60-75.